OneCell Diagnostics, a startup specializing in AI-powered cancer diagnostics, has successfully secured $16 million in Series A funding. This investment will fuel the company's expansion into the US market with its innovative liquid biopsy test, OncoIndx Alfa. OneCell's ultimate goal is to democratize precision oncology by making advanced cancer testing more accessible and affordable.
